All patients
ECOG 0 ECOG 1 Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mUC - L2 - all population, atezolizumab based treatment vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
0.85 [0.73 ; 0.99 ] IMvigor-211 (all population), 2018 1 0% 931 NA not evaluable deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
0.82 [0.71 ; 0.94 ] IMvigor-211 (all population), 2018 1 0% 931 NA not evaluable progression or deaths (PFS)detailed results IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
0.89 [0.60 ; 1.32 ] IMvigor-211 (all population), 2018 1 0% 931 NA not evaluable DORdetailed results IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
0.16 [0.07 ; 0.35 ] IMvigor-211 (all population), 2018 1 0% 124 NA not evaluable objective responses (ORR)detailed results IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
0.99 [0.68 ; 1.45 ] IMvigor-211 (all population), 2018 1 0% 931 NA not evaluable AE (any grade)detailed results IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
0.38 [0.17 ; 0.88 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable AE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
0.80 [0.62 ; 1.04 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable AE leading to death (grade 5)detailed results IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
0.91 [0.46 ; 1.79 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
0.37 [0.24 ; 0.57 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable SAE (any grade)detailed results IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
0.92 [0.70 ; 1.19 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable STRAE (any grade)detailed results IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
0.56 [0.40 ; 0.78 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable TRAE (any grade)detailed results IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
0.28 [0.19 ; 0.40 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
0.33 [0.25 ; 0.45 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable TRAE leading to death (grade 5)detailed results IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
0.42 [0.13 ; 1.39 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable TRAE leading to discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
0.22 [0.12 ; 0.38 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
0.40 [0.18 ; 0.89 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
0.42 [0.18 ; 0.97 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable Constipation TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
0.02 [0.00 ; 0.38 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
0.37 [0.15 ; 0.88 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
0.04 [0.00 ; 0.27 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
0.04 [0.01 ; 0.15 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
0.12 [0.01 ; 0.95 ] IMvigor-211 (all population), 2018 1 0% 902 NA not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-11 00:17 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 155
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866
